Abstract
Pegloticase is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals. In September 2010, the FDA approved Pegloticase for marketing in the United States after two clinical trials demonstrated that the drug lowered uric acid levels and reduceddeposits of uric acid crystals in joints and soft tissue